Pharmaceuticals

A novel therapy that disarms rather than kills a deadly superbug offers a glimpse of a post-antibiotic future for patients with a debilitating lung disease.

An acquisition signals more than growth; it’s a strategic redesign of the clinical trial landscape, challenging giants and empowering innovation.

Unauthorized antibiotics and ED drugs sold from a Montreal store reveal a dangerous black market that bypasses health regulations and puts consumers at risk.

A biometrics CRO appoints a physician-AI strategist, signaling a pivotal shift from tech hype to the deep, regulated integration of AI in drug development.

A top exec's move from a device giant to a drug startup signals a major shift. Charles Anderson analyzes why hardware's limits in fighting infection are now biotech's biggest opportunity.

Coultreon Biopharma's strategic hire of Dr. Prista Charuworn signals a major push to advance its novel SIK3 inhibitor in the crowded autoimmune market.

The dermatology giant posts strong revenue but dips in profit, channeling funds into high-impact acquisitions and R&D for underserved skin conditions.

Beyond beta-blockers, a new class of targeted therapies is revolutionizing hypertrophic cardiomyopathy care, sparking a fierce corporate race for market dominance.

A new survey reveals the staggering cost of clinical trial delays, but the real story isn't the numbers—it's the systemic breakdown of a fragmented, manual process.

The sickle cell drugmaker engineered a stunning Q2 profit, but a deep dive reveals a radical strategic bet on outsourcing its commercial backbone.

Quoin Pharmaceuticals scores key regulatory wins for its rare skin disease drugs, offering hope where none existed. But can its cash hold out long enough?

Quince Therapeutics bets its future on an inhaled lung disease drug, LAM-001, after acquiring Orphai and securing a $115M financing to fuel its new mission.

Fortress Biotech's Q2 net loss masks a cash-rich strategy. A $117M cash surge and major pipeline wins reveal a model built for the long haul.

With a $115M financing and an expanded pipeline, Assembly Biosciences is betting on novel therapies for liver and viral diseases. But can it navigate a crowded field?

A new fusion of real-time alerts and human expertise aims to stop financial leakage in drug copay programs, a move that could redefine revenue strategy.

NervGen Pharma launches its pivotal Phase 3 RESTORE trial for spinal cord injury, backed by $61M in cash and new leadership, igniting hope for a new era of neuro-repair.

Facing a 'going concern' warning, Pulmatrix abandons its drug pipeline for a reverse merger, betting its survival on the high-risk field of longevity science.

Rigel's VEPPANU is the first FDA-approved PROTAC, a new class of drug that destroys disease proteins. This is the story behind the science and the numbers.

Lurie Children's new facility is more than a pharmacy; it's a look into a new system where hospitals integrate business and care to survive and thrive.

Curis secures a crucial, albeit small, $5.6M funding lifeline. Will it be enough to push its promising cancer drug through trials before the clock runs out?